We have successfully used the BrainSim myelination assay to create human oligodendrocyte myelinating spheroids to generate one of the first pathophysiological models for demyelinating diseases. Similar to what is noted in the literature, we observed significant demyelination when the spheroids were exposed to either LPC or cuprizone. A human in vitro model such as ours, that consist of neurons, astrocytes and oligodendrocytes, with high myelination, will be an essential tool to evaluate drug targets to mitigate demyelination and/or promote remyelination and thus develop potential therapies.
Upon completion, participants will be able to understand the process of differentiating human neural progenitor cells (NPCs) into the BrainSim platform containing neurons, astrocytes, and oligodendrocytes.
Upon completion, participants will be able to define oligodendrocyte myelination and the quantification method used.
Upon completion, participants will be able to discuss the effect of demyelinating agents on oligodendrocyte myelination.